Dr Reddy's stock gains Brazil semaglutide approval opportunity

Dr. Reddy's Laboratories received marketing authorization from Brazil's National Health Surveillance Agency, ANVISA, for a generic semaglutide injection on Thursday, November 5, 2026. The Hindu BusinessLine reported that the approval covers adults with insufficiently controlled type 2 diabetes.

Approval targets Brazil diabetes demand

The treatment is intended to be used alongside diet and exercise. It may be prescribed alone when metformin is unsuitable because of intolerance or contraindications, or together with other diabetes medicines.

Dr. Reddy's said the product will be supplied as a pre-filled, multi-dose injectable pen for once-weekly use. The company plans two presentations, 2 mg/1.5 mL and 4 mg/3 mL. Brazil has 16.6 million adults aged 20 to 79 living with diabetes, while the company's release estimates the country's diabetes semaglutide market at approximately USD 244.6 million.

Launch partnership sets next milestone

MV Ramana, chief executive officer of Global Generics at Dr. Reddy's, said the company plans to launch semaglutide in Brazil with Aché. The authorization expands the company's semaglutide strategy into another Latin American market, but the approval itself does not establish a launch date or sales contribution.

Global pharmaceutical platform

Dr. Reddy's is headquartered in Hyderabad, India, and operates across generics, API and services, innovative medicines, and consumer health. Its portfolio includes branded and unbranded generics, biosimilars, research support, and licensed products. The business is positioned in global pharmaceuticals, with generics and biosimilars forming its core access-oriented platform alongside innovative and consumer health activities.

India's broader equity market context is covered in the BSE Sensex market overview.

More news and analyses on Dr Reddy's stock